Soliris® (eculizumab) Net Product Sales Increased 36 Percent to
Steady Soliris Growth in PNH Worldwide
aHUS Launch Progresses in US and Europe; Japan Launch Begins in Q4
Guidance Revised Upward for 2013 Revenues and Non-GAAP EPS
Strong Progress in Pipeline Programs, cPMP Replacement Therapy
Receives FDA Breakthrough Therapy Designation
Q3 2013 net product sales increased 36 percent to $400.4 million,
compared to $294.1 million in Q3 2012.
Q3 2013 GAAP net income increased to $93.8 million, or $0.47 per
share, compared to net income of $92.2 million, or $0.46 per share, in
Q3 2012. Q3 2013 GAAP EPS included a decrease of $0.10 per share
related to expenses from both a license agreement and a litigation
settlement. Q3 2012 GAAP EPS included an increase of $0.13 per share
related to the net effect of an intellectual property settlement and
an impairment loss.
Q3 2013 non-GAAP net income increased 39 percent to $167.9 million, or
$0.83 per share, compared to Q3 2012 non-GAAP net income of $120.7
million, or $0.60 per share.
Third Quarter 2013 Financial Highlights:
CHESHIRE, Conn.--(BUSINESS WIRE)--
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced financial
results for the three and nine months ended September 30, 2013. The
Company reported net product sales of Soliris® (eculizumab)
of $400.4 million in the third quarter of 2013, an increase of 36
percent from the same period in 2012.
Revenue performance for the quarter reflected steady additions of new
patients with paroxysmal nocturnal hemoglobinuria (PNH) globally, and an
increasing number of new patients with atypical hemolytic uremic
syndrome (aHUS) commencing Soliris treatment in the US and Europe.
“In the third quarter, we continued our strong and ongoing global
performance with Soliris in PNH and were pleased to provide Soliris to a
steadily growing number of new patients with aHUS in the United States
as well as an increasing number of patients with aHUS in Europe. In
addition, we were pleased to receive our aHUS approval in Japan,” said
Leonard Bell, M.D., Chief Executive Officer of Alexion. “Key pipeline
initiatives, including our asfotase alfa program in HPP, our Soliris
programs in kidney transplant and our cPMP replacement therapy program,
reached new milestones in Q3. In Q4, we are further expanding our
commercial and clinical initiatives as we prepare for further growth in